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Introduction 
The instrumentation used in respiratory care is 
among the most technologically advanced in 
medicine. Only advanced imaging techniques rival 
the technological changes that have occurred in the 
past decade in respiratory care. As a result, 
professionals involved in respiratory care have a 
responsibility to their patients and to themselves to 
use this new technology safely and effectively. Because 
there is a growing concern that medical technologies 
may be inappropriately used, there is an increasing 
need to make self-assessments of where we are and 
where the application of new technologies is leading 
us. 
Because of concerns that manufacturers might 
produce inappropriate medical devices, in May 1976 
the Congress of the United States enacted the Medical 
Device Amendment to the federal Food, Drug, and 
Cosmetic Act (PL 94-295). 1'2 The primary purpose 
of the amendment was to ensure that new medical 
devices were safe and effective. The law, administered 
by the Food and Drug Administration (FDA), has 
been controversial and severely criticized. 1 
By law, the definition of "medical device" is all-
encompassing. Any item promoted for medical 
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purposes that is not a "drug" is considered to be 
a medical device and is classified into one of three 
general categories: 
Class I. General Control. Class I requires that 
manufacturers comply with "good manufacturing" 
practices. An example would be a bedpan. 
Class II. Performance Standards. Class II devices must 
meet federally defined performance standards. An 
example would be a spirometer. 
Class III. Life-sustaining or life-support devices. Class 
III devices are subject to the most extensive regulation. 
They cannot be marketed until the manufacturer 
demonstrates their safety and effectiveness to the 
FDA's satisfaction. An example would be a "closed-
loop" computer-controlled ventilator. 
Through classification panels, the FDA has 
identified more than 1,700 different devices, 50,000 
products, and 7,000 manufacturers. Let's look into 
the current regulatory situation as it relates to 
respiratory care practitioners. Pulmonary function 
testing equipment and methodology have recently 
been standardized and will serve as a model to surmise 
what the effects of the Device Amendment on other 
devices might be. 
Pulmonary Function Testing Standardization 
In 1846, Hutchinson performed and published 
results from spirometry testing. 3 His spirometer was 
a water-filled device for the measurement of vital 
capacity and was very similar to spirometers used 
today. With his simple instrumentation, Hutchinson 
did some interesting experiments. For example, he 
monitored and recorded the deterioration of 
pulmonary function in a giant (7' 3") American man 
who was touring England with a circus, by measuring 
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his vital capacity repeatedly for several weeks 
preceding his death. Nearly a century later (1950), 
timed measurements were added to spirometry by 
Dr Edward A Gaensler at Boston University in 
cooperation with the Warren E Collins Company.4' 5 
Gaensler's pioneering work led to the development 
of the forced vital capacity (FVC) maneuver and the 
measurement of the forced expired volume in the 
first second (FEV 1) and other time-related measures 
of dynamic pulmonary function. Since that time there 
have been a wide variety of devices developed for 
spirometry. These include the water-seal, rolling-seal, 
and bellows spirometers and Fleisch and wire-mesh 
resistor pneumotachometers. After the FVC had been 
in use for nearly 3 decades, the American Thoracic 
Society (ATS), in 1979, published recommendations 
for FVC spirometry.6 In 1987, the ATS updated its 
spirometry recommendations. 7 
Based on the Medical Devices Amendment, which 
has been in place since 1976 and the spirometry 
standard that was published in 1979, the following 
5 questions are posed: 
1. Was there a need for standardization of 
spirometers in 1979? Yes. Based on the results of 
spirometer testing done in 1979, only 70% of the 
volume spirometers met A TS recommendations, and 
none of the flow devices performed acceptably.8 
2. Has the state of the art of spirometer instrumen-
tation improved since the development of standards? 
No. By 1987 the number of vendors of volume 
spirometers had dramatically increased and still only 
70% of them were found to be acceptable.9 In 1979, 
no flow-based spirometers were acceptable, whereas 
in 1987 about 30% were found to perform 
adequately.8'9 Approximately 48% of the spirometers 
marketed today perform poorly! 9 
3. Has the quality of data collected from pulmonary 
function laboratories improved to the point that 
standardization is no longer necessary? No. Based 
on results of FVC studies that I personally carried 
out at 28 different clinical laboratories in 1983, there 
is still need to improve the standardization of 
laboratory testing and quality control (Table 1). 
Spirometry by 28 different laboratories found my 
FVC to be between 4.8 and 5.2 liters (5.0 ±4%). 
Variability of ±3% of FVC is typical of trained 
subjects. 6 Thus only 1/3 of the variability is attributed 
to poor test equipment and/ or measurement 
technique. In the 4 years following publication of 
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recommendations for instrumentation and test 
performance ( 1980-1983), this variability was judged 
acceptable. 
On the other hand, the single breath diffusion 
capacity for the lung (DLCOss) measurement, which 
had not been standardized, showed a huge variability 
in both the predicted (±17%) and measured values 
( ±21% ). It appears from these preliminary findings 
that standardization of equipment and procedures can 
improve the quality of data collected. Recently the 
A TS has presented recommendations for standardi-
zation of the DLCOss test, 10 pulmonary function 
.• 6710 111 l" testmg eqmpment, ' ' personne , qua 1ty assu-
rance, 
12 
and the use of computers in the pulmonary 
f . l b 7 13 unction a oratory. ' 
4. How should pulmonary function devices be 
tested? The ATS has developed excellent 
performance-testing recommendations for 
spirometry,6' 7 which should be used. The questions 
of who does performance testing and how it is done 
are very important considerations. At the moment 
there are several possible places where such 
performance evaluations might be done. 
The Emergency Care Research Institute (ECRI), 
a non-profit organization in the Philadelphia area, 
tests health devices and publishes results of 
evaluations. Health Devices is its monthly publication, 
available to hospitals and health care facilities. 
Consumer Reports, a national publicatiOn, 
generally does not get into the details of evaluation 
deeply enough to satisfy scientific inquiry. 
Scientific papers published in refereed journals are 
a likely source of current information on medical 
device performance. 
Independent laboratories in the private sector have 
recently been recommended by the ATS as approp-
riate agencies to perform testing of spirometers. The 
precedent for such independent testing has already 
been established by Underwriters Laboratory (UL). 
Table I. Pulmonary Function Test Results, Range of Predicted 
and Measured Values on the Same Subject at 28 




(mil min/ torr) 
Predicted 
4.3 to 5.5 
28.0 to 40.0 
Measured 
4.8 to 5.2 
28.0 to 43.3 
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Government agencies have also tested and 
evaluated devices and systems. 
Several years ago, Dr John L Hankinson of the 
National Institute of Occupational Safety and Health 
in Morgantown, West Virginia, developed a 
hydraulically driven syringe for testing spirometers. 
This spirometer testing device, which cost about 
$35,000, was used by my group in evaluating 
commercially available spirometers in the late 1970s. 8 
More recently, Steven B Nelson at the University 
of Utah has developed a stepper-motor-controlled 
device costing only $7,000 that can be purchased 
by manufacturers and testing laboratories. 
Methods for testing spirometers have recently been 
outlined by the A TS. 7 The 24 standardized testing 
waveforms proposed by the ATS consist of a variety 
of challenging, actual-patient spirograms, which cover 
situations that might occur in a wide variety of clinical 
situations, and specifically test the ability of 
spirometers to measure 'difficult' waveforms. 
Testing of medical devices such as spirometers 
against standards is a sensitive issue, both from the 
legal and ethical viewpoints. Clearly, legal protection 
must be provided to the testing laboratory, and 
manufacturers need assurance that fair and accurate 
testing is done, without human prejudice. The criteria 
for testing must be explicitly stated, and the validation 
of testing devices must be made clear. At the moment, 
it appears that institutions such as ECRI, which have 
experience with the legal and ethical procedures 
involved in product testing, are probably the best 
agencies to test new medical devices. From the ethical 
standpoint, patients deserve to have accurate and 
reliable testing performed on them. It is a common 
belief of the scientific community that no data are 
better than bad data. Inaccurate measurements of vital 
data could lead physicians to make incorrect 
diagnostic and therapeutic decisions. 
To give an example of how important the legal 
issues are, our spirometer testing project resulted in 
the filing of a $90 million lawsuit against the 
University of Utah, graduate student Steven B Nelson, 
and myself. Headlines in the April 3, 1987, Daily 
Utah Chronicle stated, "The University of Utah, a 
professor, and graduate student have been named 
defendants in a $90 million lawsuit filed in U.S. 
District Court." Clearly this type of action by a 
manufacturer has dampened my own personal interest 
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in medical device testing and may dissuade others 
from getting into the medical device testing field. 
5. What should be done by professional societies 
and the FDA to improve the quality of pulmonary 
function instrumentation and data? The Medical 
Devices Amendment of 1976 has not totally 
eliminated the manufacture and sale of inaccurate 
spirometers. In my opinion, these results are a sad 
commentary on the spirometry industry. The 
responsibility of providing accurate spirometers must 
be shared by both the manufacturer and the user. 
The A TS and the American Association for 
Respiratory Care (AARC) need to express their 
concern for the lack of adequate spirometer 
performance to manufacturers, and they need to work 
with them to improve the quality of available 
instrumentation. 
Opportunities for Standards Development 
The first 'warning shot' has been fired. Represen-
tatives of the U.S. government felt that industry and 
professional societies had not done the job well and 
thus gave authority to the FDA to police the industry. 
We, as professionals, must get more involved in setting 
standards for the industry-or others, less sensitive 
to our needs, will develop criteria that may cause 
discomfort to us all. 14 
The AARC has a unique opportunity to become 
involved in setting standards for two new and exciting 
groups of devices. The first involves setting up 
communication standards for ventilator and respira-
tory monitoring equipment. The second relates 
specifically to the use and validation of pulse 
oximeters. 
Ventilator and Monitoring 
Communication Standards 
Care of the acutely ill patient requires data from 
a wide variety of devices and instruments. 15- 23 For 
example, it is not unusual for a patient in the ICU 
to be connected to a bedside cardiac monitor, a non-
invasive blood pressure monitor, several infusion 
pumps, a ventilator, a pulse oximeter, and a urine-
output measuring system. Each of these devices may 
be made by a different manufacturer, and each has 
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a different computerized communications interface. 
Currently, different manufacturers may use different 
algorithms or time constants to calculate derived 
indices (eg, compliance). Various manufacturers have 
also developed their own communications protocols 
and methods of formatting their data. For example, 
some manufacturers transmit data strings with 
headers, while others send only data strings. Although 
this may appear on the surface to be a trivial problem, 
it can be serious when one is trying to get two devices 
to communicate. A medical information bus (MIB) 
has been proposed to help solve this problem by 
providing a local area network around the patient 
that acquires data from all of the bedside devices. 16 
Clinician-members of the AARC have not yet become 
involved in the development of these standards. The 
final details of the MIB and its computerized 
communications protocol are still under development. 
To make the network scheme work, development 
of industry-wide standards is essential. The Institute 
of Electrical and Electronic Engineers (IEEE) has 
a MIB committee (IEEE Pl073) that is actively 
working in this area. 
Manufacturers are not motivated to develop 
common communications standards. I believe that 
they would rather force us to use their equipment-
thus eliminating their competition. What happens to 
us as users is that either (1) we pay a premium price 
for compatible devices that we are forced to buy 
from the primary manufacturer, (2) we do not get 
the monitoring or measuring device at all, or (3) we 
are not able to integrate the data from multiple devices 
conveniently. 
There is a critical need to integrate data for patient 
care needs, quality control, staff management, and 
development of on-line charge-capture mechanisms. 
The cost of acquiring data is high. We must become 
efficient as we care for the more acutely ill patient. 
We must document more and better ways to satisfy 
the quality-of-care and legal issues. 
Most manufacturers have not yet caught the vision 
of the importance of integrating data from multiple 
sources. As members of the scientific medical 
community, we must educate our profession and the 
industry to the exciting opportunities that an 
integrated communications network would make 
available to us. We must also work harder at providing 
accurate and valid data from respiratory devices. 
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Currently, too many false-positive alarms and too 
much 'noise' are being sent by bedside monitors to 
computerized data bases. 16'22' 23 
The Pulse Oximeter: 
A Medical Device 
in Need of Standardization 
The pulse oximeter is one of the most exciting 
and potentially valuable devices to enter the 
respiratory monitoring field in recent years.24- 28 The 
pulse oximeter is a device that provides clinically 
important data noninvasively in a timely fashion. By 
pulsing red and infrared light through the finger or 
ear and by using a detecting photodiode, the device 
measures oxygen saturation beat by beat. A self-
contained display provides a continuous readout of 
data, or the device can communicate the data to a 
central computer data base. However, despite all its 
potential advantages, the pulse oximeter is a device 
in need of standardization. 
There are currently more than 30 manufacturers 
of pulse oximeters. How does one know which device 
is satisfactory for clinical use? To determine the 
answer to this question, methods (standards) must 
be developed to determine: 
1. How should the pulse oximeter be tested (bench 
vs clinical)? 
2. What testing should be done? 
3. Who should do the testing? 
4. How and where should pulse oximeters be used? 
5. How can one assure that the saturation data 
reported are accurate? 
The AARC is in the best position of any group 
in this country to establish performance standards 
for pulse oximeters. I believe that if the AARC or 
other professional groups do not establish the 
standards, then manufacturers will continue to 
produce anything they can sell. As a consequence, 
the product supplied may not be in the best 
professional or patient interest. Although clinical use 
of data from pulse oximeters is widespread, careful 
clinical evaluation is still lacking. To address some 
issues of clinical requirements of monitoring, a group 
of anesthesiologists recently proposed standards for 
anesthesia monitoring. 29 
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Conclusion 
The establishment of standards by private 
professional groups is the best way to regulate the 
medical device industry. There is strong evidence that 
the FDA also agrees with this philosophy. In July 
1986, the FDA offered a "cooperative agreement and 
availability of funds" to establish standards for Class 
II devices. 30 At the end of 1987, the development 
of an apnea-device standard by ECRI was the only 
project that had been funded. Recently, the FDA 
withdrew its requirements for development of a 
mandatory electrical safety standard because it felt 
that existing voluntary standards were being adhered 
to by manufacturers.3 1 One of the primary voluntary 
standards in the electrical safety field was developed 
by the Association for the Advancement of Medical 
Instrumentation (AAMI). The FDA's recent publi-
cation of "FDA Policy for Regulation of Computer 
Products" is further evidence that the FDA is willing 
to back off from its strict mandatory performance 
standards if the industry will be responsive and 
"bl 32 respons1 e. 
Why then should the AARC be involved in the 
development of standards for the respiratory care 
industry? The AARC has the technical expertise to 
develop and set standards in this technologically 
complex field. The AARC can control its own destiny 
by establishing reasonable and prudent standards. If 
the AARC does not, others will. The AARC can 
assist manufacturers to better deliver quality products. 
Manufacturers do not have open access to the clinical 
scene and can learn much from health care 
professionals such as AARC members. With 
establishment of communications standards, we will 
be able to better-more efficiently, effectively, and 
accurately-transmit data from respiratory devices to 
computerized data bases. 
How should the AARC become involved? There 
are several steps that can be taken by AARC 
leadership. First, in my opinion, the AARC should 
begin, through its Standards Committee or some other 
mechanism, by making recommendations on 
standardization of communications protocols and 
pulse oximetry. Second, the AARC should participate 
with existing standardization groups such as the 
Association for the Advancement of Medical 
Instrumentation (AAMI), American National 
Standards Institute (ANSI), National Committee for 
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Clinical Laboratory Standards (NCCLS), Food and 
Drug Administration (FDA), American Society for 
Testing Materials (ASTM), and Institute of Electrical 
and Electronic Engineers (IEEE). Finally, the AARC 
should work with industry to validate standards with 
clinical trials and clinical demonstrations. 
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